CN102836146A - Application of sodium ferulate in preparation of medicaments for treating schizophrenia - Google Patents
Application of sodium ferulate in preparation of medicaments for treating schizophrenia Download PDFInfo
- Publication number
- CN102836146A CN102836146A CN2012102126842A CN201210212684A CN102836146A CN 102836146 A CN102836146 A CN 102836146A CN 2012102126842 A CN2012102126842 A CN 2012102126842A CN 201210212684 A CN201210212684 A CN 201210212684A CN 102836146 A CN102836146 A CN 102836146A
- Authority
- CN
- China
- Prior art keywords
- sodium ferulate
- medicaments
- treatment
- side effects
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of pharmaceuticals, and in particular relates to an application of sodium ferulate in preparation of medicaments for treating schizophrenia. The medicament treatment for schizophrenia has a plurality of problems of large medicament side effects, poor treatment compliance, high recurrence rate and high disability rate; and the large medicament side effects cause poor treatment compliance, high recurrence rate and high disability rate. The invention provides the technical scheme for solving the problems. When sodium ferulate is separately used, and is particularly used for intravenous injection of sodium ferulate, so a corresponding curative effect with low side effects and high treatment compliance can be obtained. By combining with the existing medicaments, sodium ferulate is applied to reduce the side effects of the existing medicaments can be greatly reduced, and meanwhile, the same curative effect is obtained, so the medicaments or complementary medicaments for treating schizophrenia have a very bright prospect.
Description
Technical field
The present invention relates to medical technical field, is that sodium ferulate is used to prepare the purposes of treating schizoid medicine.
Background technology
Sodium ferulate is the water-soluble active ingredient that from Radix Angelicae Sinensis or Rhizoma Chuanxiong, extracts, and claims that again angelicin or Rhizoma Chuanxiong are plain, has pharmacological action widely; Mainly be synthetic now, chemical name 3-methoxyl group-4-Hydroxycinnamic Acid sodium has antiplatelet aggregation; Suppress the platelet 5-hydroxy tryptamine and discharge, suppress the generation of the plain a2 of platelet thrombus (txa2), it is active to strengthen prostaglandin; Analgesia, pharmacological actions such as alleviating vascular spasm.At present, sodium ferulate be mainly used in cardiac and cerebral vascular diseases such as atherosclerosis, coronary heart disease, cerebrovascular, renal glomerular disease, pulmonary hypertension, diabetic angiopathy change, vasculitis, migraine, vascular headache treatment.So far not seeing has sodium ferulate to be used to treat schizoid report.
Schizophrenia (schizophrenia) is a kind of psychiatric department disease; It is a kind of lasting, common chronic great mental sickness; Be the most serious a kind of in the psychosis; Be with basic individual character, the division of thinking, emotion, behavior, the inharmonious of ergasia and environment is one type of modal psychosis of principal character.The prevalence of primary disease is the highest a kind of of prevalence in the psychosis.In China 8,000,000 patients are arranged approximately, schizoid high relapse rate has become the focus that world health is paid close attention to.Because the characteristic of disease itself, schizophrenia are a kind of chronic persistent diseases of outbreak repeatedly, the state of an illness easily repeatedly.Recurrence each time all might cause the permanent damage of patient's brain, and cognitive function is further impaired, social function further descends; For family numbers of patients, recurrence means the deterioration of relatives' state of an illness and repeatedly enforceable hospitalization, must bear bigger financial burden and causalgia; For the medical personnel, recurrence can increase the difficulty of treatment, and final prognosis is undesirable.Therefore effectively the recurrence of prevention of schizophrenia has become the urgent problem that solves of needs.
Improve the compliance of treatment of schizophrenia, could help the patient to return society.Secular Drug therapy makes the schizophrenic that treatment is lost confidence easily.Frequent miss medicine and must cause disease relapse, even worsen and the hospitalization once more of having to.After patient's recurrence several times, each cycle state of an illness is recovered meeting needs the longer time, and the curative effect of antipsychotic drug also can decrease, and As time goes on, the difficulty of treatment increases gradually.
The compliance of medicine is successfully to treat one of schizoid key factor, and is therefore very important to treatment schizophrenia through the compliance of making great efforts to improve the patient in many ways.
The side effect low and medicine all the time of schizophrenic's treatment compliance is in close relations.Present schizophrenia drug is by pharmacological action, and the clinical anti-smart medicine that divides commonly used is divided into two types of typical case and atypia.The anti-smart medicine that divides of typical case claims tradition the anti-smart medicine that divides again; Represent medicine that chlorpromazine, haloperidol etc. are arranged, this type medicine is better to positive symptom therapeutic effect, but invalid to negative symptoms; Treatment is often followed more serious The extrapyramidal symptoms (EPS) simultaneously, and patient's compliance is relatively poor.The anti-smart medicine that divides of atypia is claimed the non-traditional anti-smart medicine that divides again; The treatment spectrum is wider, and the negative symptoms effect obviously is superior to conventional medicament, and side effect is little in a short time; But life-time service can cause weight increase; Lipid and abnormal carbohydrate metabolism trend increase, and are worth thereby influence long-term treatment, and serum prolactin antagonist rising, Q-T interval prolongs equally also and can have a strong impact on patients ' life quality; Reduce the compliance of taking.
The object of the invention just is to obtain the low side effect of situation decline of certain curative effect, improves the compliance of treatment.Clinical observation shows no matter be to use separately or the Combined application sodium ferulate, can both obtain certain curative effect and keep low-down side reaction, therefore can well improve the compliance of treatment.
Summary of the invention
Claim item 1, sodium ferulate are used to prepare the purposes of treating schizophrenia drug.
Claim item 2, based on claim item 1, the compositions that mainly comprises sodium ferulate is used to prepare the purposes of treating schizophrenia drug.
Claim item 3, sodium ferulate are used to prepare the purposes of treating schizoid ancillary drug.
Claim item 4, based on claim item 3, the compositions that mainly comprises sodium ferulate is used to prepare the purposes of treating schizoid ancillary drug.
Problem to be solved by this invention is to improve schizoid symptom and in the improvement process, do not produce or significantly reduce The extrapyramidal symptoms and react with other lipid and abnormal carbohydrate metabolism.Technical scheme provided by the invention is that sodium ferulate is used to prepare the purposes of treating schizophrenia drug.Clinical observation shows no matter be to use separately or the Combined application sodium ferulate, can both when obtaining certain curative effect, keep low-down side reaction, therefore can well improve the compliance of treatment.
Below, through embodiment the present invention is elaborated.But not only be confined to these examples.
Embodiment 1: the schizoid medicine of sodium ferulate preparation treatment: sodium ferulate is added excipient, process tablet by conventional method.
Embodiment 2: the schizoid medicine of sodium ferulate preparation treatment: sodium ferulate is added water for injection, process injection by conventional method.
Clinical observation 1:
1 object and method
1.1 the object case selects patient 46 to fall, and meets CCMD-2-R schizophrenia diagnosis standard, BPRS (BPRS)>35, male: women (24:22), mean age (32.4 soil 6.8) year, average course of disease (2.8 soil 3.2) year.
1.2 method is divided into treatment group and matched group at random.The treatment group uses sodium ferulate 500mg to add 5% glucose 250ml intravenous drip.Matched group uses 0.9% sodium chloride 250ml intravenous drip.25 days is a course of treatment.Treatment group 24 is fallen matched group 22 examples.Two groups are carried out the BPRS scoring respectively before and after the treatment.
Statistical procedures is carried out statistical disposition with SPSS 13.0 software kits; Measurement data is represented with mean ± standard deviation (
); Relatively adopt the check of two independent sample t between two groups, relatively use pairing design t check before and after the treatment.P＜0.05 is for difference has significance, and there is the utmost point significance P＜0.01 for difference.
Table 1 is seen in two groups of BPRS scorings.By table 1 finding, each items compare before two groups of patient treatments, through t check there are no significant difference (P is equal>0.05).After the treatment, the result finds that the patient B PRS score value of treatment group 74.3% has sizable decline, and matched group then improves not obvious.Two groups of indexs relatively have significant difference (P < 0.05).
Table 1 liang group BPRS scoring (
)
Annotate: compare ※ P＜0.01 with matched group
Side reaction 1 example appears in the treatment group, accounts for 4.2%, is headache, and untreated and drug withdrawal are promptly alleviated.
Clinical observation 2:
1 object and method
1.1 the object object of study is my institute's inpatient, goes into the group standard and meets Chinese mental sickness diagnostic criteria CCMD-II-R about schizoid diagnostic criteria, the BPRS total points>35 minutes; Do not merge simultaneously serious physical disease, routine blood test, liver function, ECG are normal.Go into to organize case 196 examples, patient age 17～52 years old, year mean age (31.5 ± 14.6); The course of disease 1～26 year, average (8.3 ± 9.5) year.Get into treatment group, matched group at random, 28 examples are organized in treatment, matched group 24 examples.Two groups of ages, the course of disease, the preceding BPRS total points of treatment are relatively checked the equal not statistically significant P of difference through t>0.05.
1.2 dividing, takes for 2 times method matched group chlorpromazine average every day of 400-600mg; Treatment group chlorpromazine average every day of 400-600mg divides and takes for 2 times, adds sodium ferulate 600mg and divides and take for 2 times, and 8 weeks were a course of treatment.
2 results
2.1 curative effect treatment group obvious effective rate 65%, matched group obvious effective rate 61%.Two groups of effective percentage comparing difference not statistically significant P>0.05.
2.2 the evaluation result of the average total points of BPRS of two groups of patient front and back: see table 2
Table 2 BPRS evaluation result
| Group | Before the treatment | After the treatment |
| The treatment group | 45.13±8.52 | 29.75±6.72 |
| Matched group | 46.02±8.63 | 30.32±7.13 |
| The p value | p>;0.05 | p>;0.05 |
Side reaction 23% appears in the treatment group, and the extrapyramidal system side reaction accounts for wherein 70%; Side reaction 86.5% appears in matched group, all is the different extrapyramidal system side reaction of degree.
Claims (4)
1. sodium ferulate is used to prepare the purposes of treating schizoid medicine.
2. based on claim item 1, the compositions that mainly comprises sodium ferulate is used to prepare the purposes of treating schizoid medicine.
3. sodium ferulate is used to prepare the purposes of treating schizoid ancillary drug.
4. based on claim item 3, the compositions that mainly comprises sodium ferulate is used to prepare the purposes of treating schizoid ancillary drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210212684.2A CN102836146B (en) | 2012-06-26 | 2012-06-26 | Application of sodium ferulate in preparation of medicaments for treating schizophrenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210212684.2A CN102836146B (en) | 2012-06-26 | 2012-06-26 | Application of sodium ferulate in preparation of medicaments for treating schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102836146A true CN102836146A (en) | 2012-12-26 |
| CN102836146B CN102836146B (en) | 2014-05-07 |
Family
ID=47364051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210212684.2A Expired - Fee Related CN102836146B (en) | 2012-06-26 | 2012-06-26 | Application of sodium ferulate in preparation of medicaments for treating schizophrenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102836146B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159035A (en) * | 2016-12-29 | 2018-06-15 | 天津中医药大学 | The new application of cinnamic acid derivative |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562167A (en) * | 2004-03-31 | 2005-01-12 | 冯其裕 | Medication for curing disease of stomach intestine |
| CN101309682A (en) * | 2005-10-21 | 2008-11-19 | 脑细胞股份有限公司 | Modulation of neurogenesis by pde inhibition |
-
2012
- 2012-06-26 CN CN201210212684.2A patent/CN102836146B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562167A (en) * | 2004-03-31 | 2005-01-12 | 冯其裕 | Medication for curing disease of stomach intestine |
| CN101309682A (en) * | 2005-10-21 | 2008-11-19 | 脑细胞股份有限公司 | Modulation of neurogenesis by pde inhibition |
Non-Patent Citations (2)
| Title |
|---|
| 《Brain Research Bulletin》 20110720 Ying-jin Zhang等 Ferulic acid-induced anti-depression and prokinetics similar to Chaihu-Shugan-San via polypharmacology 第222-228页 1-4 , * |
| YING-JIN ZHANG等: "Ferulic acid-induced anti-depression and prokinetics similar to Chaihu–Shugan–San via polypharmacology", 《BRAIN RESEARCH BULLETIN》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159035A (en) * | 2016-12-29 | 2018-06-15 | 天津中医药大学 | The new application of cinnamic acid derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102836146B (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rigg et al. | Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial | |
| Braunwald et al. | Contemporary evaluation and management of hypertrophic cardiomyopathy | |
| Roth | Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke | |
| Somocurcio et al. | Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru | |
| Jiang et al. | Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis | |
| Chen et al. | Comparative analysis of diabetic nephropathy and non-diabetic nephropathy disease | |
| Acharya et al. | Lithium-Induced cardiotoxicity: a rare clinical entity | |
| CN102836146B (en) | Application of sodium ferulate in preparation of medicaments for treating schizophrenia | |
| Wang et al. | Systematic review and meta-analysis on the efficacy and safety of injectable lentinan combined with chemotherapy in the treatment of gastric cancer | |
| CN100388950C (en) | Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction | |
| Wang et al. | Efficacy of volume-based feeding (VBF) protocol on critically ill patients: A meta-analysis and systematic review | |
| Sun et al. | A literature analysis on 14 cases of allergic shock caused by safflower injection | |
| Liang et al. | Effect of alprostadil plus cilostazol on the treatment outcomes and inflammatory factors in patients with lower extremity arteriosclerosis obliterans receiving evidence-based care | |
| Agrawal et al. | Tricyclic antidepressant overdose | |
| CN103211802A (en) | Novel application of phloroglucinol | |
| CN103989779B (en) | A kind of Radix Angelicae Sinensis CHENGQI TANG merges lithium carbonate group compound and application thereof | |
| Lin et al. | Clinical Observation and Nursing of Bisoprolol in the Treatment of Pulmonary Heart Disease and Heart Failure Based on Microscope. | |
| Lu et al. | Effect of hypertransfusion on the gastrointestinal tract after cardiac arrest in a porcine model | |
| Masopust et al. | Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson's disease | |
| Ramadan et al. | Feasibility of Targeting Lactate Clearance versus Central Venous Oxygen Saturation during Early Resuscitation of Septic Patients | |
| Gholami et al. | A Case report of hemodynamic instability, cardiac arrest, and acute severe dyspnea subsequent to inhalation of crystal methamphetamine | |
| Shahrestani et al. | 497 Developing Predictive Models to Anticipate Shunt Complications in 33,248 Pediatric Patients with Shunted Hydrocephalus Utilizing Machine Learning | |
| Patel et al. | S133 The assessment of health related quality of life in interstitial lung disease with the King's brief interstitial lung disease questionnaire (K-BILD) | |
| Gao et al. | Efficacy and Safety of Bushenjiangya‐Optimized Granule for Left Ventricular Diastolic Dysfunction in Hypertensive Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial | |
| Zheng et al. | Investigation of The Effect of Ticagrelor Combined with Alprostadil in The Treatment of Angina Pectoris in Coronary Artery Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140507 Termination date: 20170626 |